The vice president of Neuroscience and Vaccines at Takeda discusses the clinical significance of oveporexton's FDA approval and how restoring orexin signaling may reshape treatment expectations in narcolepsy type 1.
Sara Sarkey, PhD
Advertisement
Articles by Sara Sarkey, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
ELEVIDYS Shows Functional Benefits in Patients With DMD, Dompé Launches Phase 2 Trial of Intranasal Nerve Growth Factor in CP, NeurologyLive Roundtable: The Road Ahead for Precision Medicine in MS
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial
4
RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial
5